Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Marcus Schuchmann

Showing results (71-80 of 85) with videos related to

Pageof 9
Sort By:
Antimicrobial Agents and Chemotherapy|April 9, 2014
SILEN-C3, a phase 2 randomized trial with faldaprevir plus pegylated interferon α-2a and ribavirin in treatment-naive hepatitis C virus genotype 1-infected patientsDouglas Dieterich, Tarik Asselah, Dominique Guyader, et al.
Scandinavian Journal of Gastroenterology|April 5, 2012
Prognostic factors and outcomes of patients with hepatocellular carcinoma in non-cirrhotic liverMarcus A Wörns, Timon Bosslet, Anja Victor, et al.
International Journal of Oncology|February 27, 2013
Downregulation of organic cation transporter 1 (SLC22A1) is associated with tumor progression and reduced patient survival in human cholangiocellular carcinomaAnja Lautem, Michael Heise, Andreas Gräsel, et al.
Transplant International : Official Journal of the European Society for Organ Transplantation|April 17, 2007
Efficacy of an escalating dose regimen of pegylated interferon alpha-2a plus ribavirin in the early phase of HCV reinfection after liver transplantationTim Zimmermann, Wulf O Böcher, Stefan Biesterfeld, et al.
Plos One|June 10, 2015
Treatment Extension of Pegylated Interferon Alpha and Ribavirin Does Not Improve SVR in Patients with Genotypes 2/3 without Rapid Virological Response (OPTEX Trial): A Prospective, Randomized, Two-Arm, Multicentre Phase IV Clinical TrialBenjamin Heidrich, Hans-Jörg Cordes, Hartwig Klinker, et al.
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|December 19, 2012
No beneficial effect of all-trans retinoic acid in previous non-responder patients with chronic hepatitis C: the ATRACTION study, a phase II randomised trialMarcus Schuchmann, Jens M Kittner, Jörg F Schlaak, et al.
Cardiovascular and Interventional Radiology|November 13, 2009
Prospective randomized study of doxorubicin-eluting-bead embolization in the treatment of hepatocellular carcinoma: results of the PRECISION V studyJohannes Lammer, Katarina Malagari, Thomas Vogl, et al.
The New England Journal of Medicine|August 16, 2013
Faldaprevir and deleobuvir for HCV genotype 1 infectionStefan Zeuzem, Vincent Soriano, Tarik Asselah, et al.
Plos One|December 10, 2015
ITPA Genotypes Predict Anemia but Do Not Affect Virological Response with Interferon-Free Faldaprevir, Deleobuvir, and Ribavirin for HCV InfectionTarik Asselah, Stefan Zeuzem, Vicente Soriano, et al.
Open Forum Infectious Diseases|March 15, 2016
Saccharomyces boulardii to Prevent Antibiotic-Associated Diarrhea: A Randomized, Double-Masked, Placebo-Controlled TrialStephan Ehrhardt, Nan Guo, Rebecca Hinz, et al.
Pageof 9

Showing results (71-80 of 85) with videos related to

Sort By:
Pageof 9
Antimicrobial Agents and Chemotherapy|April 9, 2014
SILEN-C3, a phase 2 randomized trial with faldaprevir plus pegylated interferon α-2a and ribavirin in treatment-naive hepatitis C virus genotype 1-infected patientsDouglas Dieterich, Tarik Asselah, Dominique Guyader, et al.
Scandinavian Journal of Gastroenterology|April 5, 2012
Prognostic factors and outcomes of patients with hepatocellular carcinoma in non-cirrhotic liverMarcus A Wörns, Timon Bosslet, Anja Victor, et al.
International Journal of Oncology|February 27, 2013
Downregulation of organic cation transporter 1 (SLC22A1) is associated with tumor progression and reduced patient survival in human cholangiocellular carcinomaAnja Lautem, Michael Heise, Andreas Gräsel, et al.
Transplant International : Official Journal of the European Society for Organ Transplantation|April 17, 2007
Efficacy of an escalating dose regimen of pegylated interferon alpha-2a plus ribavirin in the early phase of HCV reinfection after liver transplantationTim Zimmermann, Wulf O Böcher, Stefan Biesterfeld, et al.
Plos One|June 10, 2015
Treatment Extension of Pegylated Interferon Alpha and Ribavirin Does Not Improve SVR in Patients with Genotypes 2/3 without Rapid Virological Response (OPTEX Trial): A Prospective, Randomized, Two-Arm, Multicentre Phase IV Clinical TrialBenjamin Heidrich, Hans-Jörg Cordes, Hartwig Klinker, et al.
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|December 19, 2012
No beneficial effect of all-trans retinoic acid in previous non-responder patients with chronic hepatitis C: the ATRACTION study, a phase II randomised trialMarcus Schuchmann, Jens M Kittner, Jörg F Schlaak, et al.
Cardiovascular and Interventional Radiology|November 13, 2009
Prospective randomized study of doxorubicin-eluting-bead embolization in the treatment of hepatocellular carcinoma: results of the PRECISION V studyJohannes Lammer, Katarina Malagari, Thomas Vogl, et al.
The New England Journal of Medicine|August 16, 2013
Faldaprevir and deleobuvir for HCV genotype 1 infectionStefan Zeuzem, Vincent Soriano, Tarik Asselah, et al.
Plos One|December 10, 2015
ITPA Genotypes Predict Anemia but Do Not Affect Virological Response with Interferon-Free Faldaprevir, Deleobuvir, and Ribavirin for HCV InfectionTarik Asselah, Stefan Zeuzem, Vicente Soriano, et al.
Open Forum Infectious Diseases|March 15, 2016
Saccharomyces boulardii to Prevent Antibiotic-Associated Diarrhea: A Randomized, Double-Masked, Placebo-Controlled TrialStephan Ehrhardt, Nan Guo, Rebecca Hinz, et al.
Pageof 9